{"id":800510,"date":"2025-01-14T08:19:16","date_gmt":"2025-01-14T13:19:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/"},"modified":"2025-01-14T08:19:16","modified_gmt":"2025-01-14T13:19:16","slug":"cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/","title":{"rendered":"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025"},"content":{"rendered":"

<\/p>\n

Cyclo Therapeutics to Present at the 21st<\/sup> Annual WORLDSymposium\u2122 <\/i>2025<\/b><\/p>\n

Pivotal Phase 3 global study (TransportNPC\u2122) evaluating Trappsol\u00ae<\/sup> Cyclo\u2122 for Niemann-Pick Disease Type C1 (\u201cNPC1\u201d) to be highlighted in an oral presentation<\/i><\/p>\n

GAINESVILLE, Fla.–(BUSINESS WIRE<\/a>)–Cyclo Therapeutics, Inc.<\/a> (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstracts have been accepted for oral and poster presentation at the 21st<\/sup> Annual WORLDSymposium<\/i>\u2122<\/a> being held February 3-7, 2025 in San Diego, CA.<\/p>\n

\nDetails of the presentations are as follows:<\/p>\n

Oral Presentation:<\/span><\/p>\n

Title:<\/b>Trappsol\u00ae<\/sup> Cyclo\u2122: Open Label Treatment in the TransportNPC\u2122 Sub-Study in Patients Under the Age of 3 Diagnosed with Niemann-Pick Disease Type C1
\n
<\/i>Presenter:<\/b> Ronen Spiegel, MD, Clinical Associate Professor, Director of Pediatric B Department, and Co-Director Center of Rare Disease at Emek Medical Center
\n
Session: <\/b>Clinical Applications
\n
Date and Time: <\/b>Thursday, February 6, 2025 at 1:30 PM PT<\/p>\n

Poster Presentations:<\/span><\/p>\n

Title:<\/b>Trappsol\u00ae<\/sup> Cyclo\u2122 (HP\u03b2CD) for the Long-Term Treatment of Niemann-Pick Type C1: Efficacy and Safety Data from 4 Clinical Studies and the Ongoing Expanded Access Program
\n
<\/i>Presenter:<\/b> Dr. Caroline Hastings, Pediatric hematologist oncologist, Director of Neuro-oncology, and Professor of Pediatrics at UCSF Benioff Children\u2019s Hospital Oakland
\n
Session: <\/b>Clinical Applications & Rapid-Fire \u2013 Poster Session III
\n
Date and Time: <\/b>Thursday, February 6, 2025 from 3:30 \u2013 5:30 PM PT<\/p>\n

Title:<\/b>Trappsol\u00ae <\/sup>Cyclo\u2122 and NPC: Efficacy Shown Across Individual 5D Domains and Utilization of Future Assessment Tools to Demonstrate Clinically Relevant Outcomes
\n
<\/i>Presenter:<\/b> Dr. Caroline Hastings, Pediatric hematologist oncologist, Director of Neuro-oncology, and Professor of Pediatrics at UCSF Benioff Children\u2019s Hospital Oakland
\n
Session: <\/b>Clinical Applications & Rapid-Fire \u2013 Poster Session III
\n
Date and Time: <\/b>Thursday, February 6, 2025 from 3:30 \u2013 5:30 PM PT<\/p>\n

\nFor more information, please visit the conference website worldsymposia.org<\/a>.<\/p>\n

About <\/i>WORLDSymposium\u2122<\/i><\/b><\/p>\n

\nWORLDSymposium\u2122<\/i> is an annual research conference dedicated to lysosomal diseases. WORLD is an acronym that stands for We\u2019re Organizing Research on Lysosomal Diseases. Since its inception as a small group of passionate researchers in 2002, WORLDSymposium\u2122<\/i> has grown to an international research conference that attracts over 2000 participants from more than 50 countries around the globe. For more information, please visit: worldsymposia.org<\/a>.<\/p>\n

About Cyclo Therapeutics<\/i><\/b><\/p>\n

\nCyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company\u2019s Trappsol\u00ae<\/sup> Cyclo\u2122, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C1, a rare and fatal genetic disease, (NCT02939547<\/a>, NCT02912793<\/a>, NCT03893071<\/a> and NCT04860960<\/a>). The Company is conducting a Phase 2b clinical trial using Trappsol\u00ae<\/sup> Cyclo\u2122 intravenously in early Alzheimer\u2019s disease (NCT05607615<\/a>) based on encouraging data from an Expanded Access program for Alzheimer\u2019s disease (NCT03624842<\/a>). Additional indications for the active ingredient in Trappsol\u00ae<\/sup> Cyclo\u2122 are in development. For additional information, visit the Company\u2019s website: www.cyclotherapeutics.com<\/a>.<\/p>\n

Safe Harbor Statement<\/i><\/b><\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d about the company\u2019s current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as \u201canticipates,\u201d \u201cbelieves\u201d and \u201cexpects\u201d or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company\u2019s future performance include the company\u2019s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company\u2019s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company\u2019s filings with the Securities and Exchange Commission, including, but not limited to, the company\u2019s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250114456775\/en\/<\/a><\/span><\/p>\n

Investor Contact:
\n<\/b>
JTC Team, LLC
\n
Jenene Thomas
\n
(908) 824-0775
\n
CYTH@jtcir.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California Florida<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Genetics Clinical Trials Biotechnology Other Health Health Pharmaceutical Other Science Science<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025 Pivotal Phase 3 global study (TransportNPC\u2122) evaluating Trappsol\u00ae Cyclo\u2122 for Niemann-Pick Disease Type C1 (\u201cNPC1\u201d) to be highlighted in an oral presentation GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstracts have been accepted for oral and poster presentation at the 21st Annual WORLDSymposium\u2122 being held February 3-7, 2025 in San Diego, CA. Details of the presentations are as follows: Oral Presentation: Title:Trappsol\u00ae Cyclo\u2122: Open Label Treatment in the TransportNPC\u2122 Sub-Study in Patients Under the Age of 3 Diagnosed with Niemann-Pick Disease … <\/p>\n

Continue reading “Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-800510","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025 Pivotal Phase 3 global study (TransportNPC\u2122) evaluating Trappsol\u00ae Cyclo\u2122 for Niemann-Pick Disease Type C1 (\u201cNPC1\u201d) to be highlighted in an oral presentation GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstracts have been accepted for oral and poster presentation at the 21st Annual WORLDSymposium\u2122 being held February 3-7, 2025 in San Diego, CA. Details of the presentations are as follows: Oral Presentation: Title:Trappsol\u00ae Cyclo\u2122: Open Label Treatment in the TransportNPC\u2122 Sub-Study in Patients Under the Age of 3 Diagnosed with Niemann-Pick Disease … Continue reading "Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-14T13:19:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250114456775r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025\",\"datePublished\":\"2025-01-14T13:19:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/\"},\"wordCount\":759,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250114456775r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/\",\"name\":\"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250114456775r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-01-14T13:19:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250114456775r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250114456775r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/","og_locale":"en_US","og_type":"article","og_title":"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025 - Market Newsdesk","og_description":"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025 Pivotal Phase 3 global study (TransportNPC\u2122) evaluating Trappsol\u00ae Cyclo\u2122 for Niemann-Pick Disease Type C1 (\u201cNPC1\u201d) to be highlighted in an oral presentation GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstracts have been accepted for oral and poster presentation at the 21st Annual WORLDSymposium\u2122 being held February 3-7, 2025 in San Diego, CA. Details of the presentations are as follows: Oral Presentation: Title:Trappsol\u00ae Cyclo\u2122: Open Label Treatment in the TransportNPC\u2122 Sub-Study in Patients Under the Age of 3 Diagnosed with Niemann-Pick Disease … Continue reading \"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-14T13:19:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250114456775r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025","datePublished":"2025-01-14T13:19:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/"},"wordCount":759,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250114456775r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/","name":"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250114456775r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-01-14T13:19:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250114456775r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250114456775r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium\u2122 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/800510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=800510"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/800510\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=800510"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=800510"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=800510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}